绿色晚期功能化试胺的功能化
Jiayi Xu1, Yahui Zhang1, Qiling Cai2
1Key Laboratory of Molecule Synthesis and Function Discovery, College of Chemistry, Fuzhou University, Fuzhou, 350108, China.
Chemistry (Weinheim an der Bergstrasse, Germany)
|June 13, 2024
概括
一种新的,简单的方法使用二酸盐来氧化三胺的化,产生大量的中间体用于进一步的化学反应.
科学领域:
- 有机化学 有机化学
- 合成化学 合成化学
背景情况:
- 三胺在生物化学和药物发现中很重要.
- 功能化胺的高效方法对于合成复杂分子至关重要.
研究的目的:
- 开发一个快速有效的协议,用于氧化胺的氧化素化.
- 为进一步的分子加工提供多功能中间体.
主要方法:
- 使用10%的水性二 (NaClO) 来氧化胺的氧化.
- 没有金属的反应条件.
- 对于中间体,不需要进行净化.
主要成果:
- 在 tryptamines 的氧化素化中取得了高产量.
- 产生的关键化中间体.
- 证明了广泛的功能组耐受性.
- 成功应用于复杂分子的后期功能化.
结论:
- 开发了一种简单,高产和快速的氧化素化方法,用于胺.
- 该协议无金属,操作简单.
- 由此产生的中间体对于合成多样化和复杂分子非常有价值.
相关概念视频
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
3.2K
In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.2K
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Preparation of Amines: Reductive Amination of Aldehydes and Ketones
2.8K
Carbonyl compounds and primary amines undergo reductive amination first to produce imines, followed by secondary amines in the same reaction mixture, using selective reducing agents like sodium cyanoborohydride or sodium triacetoxyborohydride. Reductive amination produces different degrees of substitution of amines depending on the starting amine substrate.
2.8K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.9K
Phase I Reactions: Reductive Reactions
197
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
197
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
213
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
213

![Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)
